A RANDOMIZED, DOUBLE-BLIND TRIAL COMPARING SECUKINUMAB 300 MG AND 150 MG AT WEEK 52 IN PATIENTS WITH ANKYLOSING SPONDYLITIS WHO DID NOT ACHIEVE INACTIVE DISEASE DURING AN INITIAL 16 WEEKS OF OPEN-LABEL TREATMENT WITH SECUKINUMAB 150 MG

被引：2

作者：

Deodhar, A. ^{[1
]}

Kivitz, A. ^{[2
]}

Magrey, M. ^{[3
]}

Walsh, J. A. ^{[4
,5
]}

Mease, P. J. ^{[6
,7
]}

Greenwald, M. ^{[8
]}

Calheiros, R. ^{[9
]}

Kianifard, F. ^{[10
]}

Elam, C. ^{[11
]}

Nagar, K. ^{[12
]}

Winseck, A. ^{[9
]}

Gensler, L. S. ^{[13
]}

机构：

[1] Oregon Hlth & Sci Univ, Rheumatol, Portland, OR USA

[2] Altoona Ctr Clin Res, Altoona Arthrit & Osteoporosis Ctr, Duncansville, PA USA

[3] Case Western Reserve Univ, Univ Hosp Cleveland Med Ctr, Sch Med, Rheumatol, Cleveland, OH USA

[4] Univ Utah, Sch Med, Salt Lake City, UT USA

[5] Univ Utah, Salt Lake City Vet Affairs Med Ctr, Rheumatol, Salt Lake City, UT USA

[6] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA

[7] Univ Washington, Rheumatol, Seattle, WA USA

[8] Desert Med Adv, Rheumatol, Palm Desert, CA USA

[9] Novartis Pharmaceut, Rheumatol, East Hanover, NH USA

[10] Novartis Pharmaceut, Biostat, East Hanover, NH USA

[11] Novartis Pharmaceut, Clin Res, East Hanover, NH USA

[12] Novartis Healthcare Pvt Ltd, Biostat, Hyderabad, India

[13] Univ Calif San Francisco, Dept Med, San Francisco, CA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷

关键词：

D O I：

10.1136/annrheumdis-2022-eular.209

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

OP0023

引用

页码：16 / 17

页数：2

共 7 条

[1] Treatment optimization with secukinumab 150 mg for moderate-to-severe psoriasis in clinical practice: a single-center open-label 52-week study
Munoz-Santos, Carlos
Sola-Ortigosa, Joaquin
Guilabert, Antonio
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (05) : 615 - 617
[2] COMPARISON OF 150 MG NIZATIDINE BID OR 300 MG AT BEDTIME, AND 150 MG RANITIDINE BID IN THE TREATMENT OF GASTRIC-ULCER - AN 8-WEEK RANDOMIZED, DOUBLE-BLIND MULTICENTER STUDY
DIMARIO, F
BATTAGLIA, G
NACCARATO, R
DANGELO, A
SAGGIORO, A
DABROI, GL
VEZZADINI, P
PORRO, GB
HEPATO-GASTROENTEROLOGY, 1990, 37 : 62 - 65
[3] The Parkinson-control study: A 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
Castro-Caldas, A
Delwaide, P
Jost, W
Merello, M
Williams, A
Lamberti, P
Aguilar, M
Del Signore, S
Cesaro, P
MOVEMENT DISORDERS, 2006, 21 (04) : 500 - 509
[4] PROSPECTIVE RANDOMIZED DOUBLE-BLIND ENDOSCOPIC CLINICAL-TRIAL COMPARING RANITIDINE 150-MG BID (R-BID) WITH RANITIDINE 300-MG-HS (R-HS) IN DUODENAL-ULCER
GLEDHILL, T
IRELAND, A
DEGARA, C
ROSS, G
GEAR, P
LEICESTER, RJ
SMITH, C
GOLDING, P
COLINJONES, DG
GASTROENTEROLOGY, 1984, 86 (05) : 1089 - 1089
[5] Subcutaneous Secukinumab 150 Mg Provides Sustained Relief in Total and Nocturnal Back Pain, Morning Stiffness, Fatigue, and Low Disease Activity in Patients with Active Ankylosing Spondylitis: End-of-study (5-year) Data from the MEASURE 2 Trial
Marzo-Ortega, Helena
Miceli-Richard, Corinne
Gill, Sonja
Magrey, Marina
Machado, Paula
Shete, Abhijit
Wang, Jianyuan
Rohrer, Susanne
Deodhar, Atul
ARTHRITIS & RHEUMATOLOGY, 2020, 72
[6] Welcome: A Randomized, Double-Blind, Controlled Trial Comparing Certolizumab Pegol 400 Mg Every 2 Weeks with Every 4 Weeks for Maintenance of Response and Remission in Patients with Moderate to Severe Crohn's Disease with Secondary Failure to Infliximab
Sandborn, William J.
Vermeire, Severine
D'Haens, Geert R.
Colombel, Jean-Frederic
Fedorak, Richard N.
Spehlmann, Martina E.
Wolf, Douglas C.
Abreu, Maria T.
Mitchev, Krassimir
Jamoul, Corinne
Rutgeerts, Paul J.
GASTROENTEROLOGY, 2009, 136 (05) : A27 - A27
[7] EFFECTS OF 1 MG ONCE-WEEKLY SEMAGLUTIDE ON FUNCTIONAL CAPACITY IN PATIENTS WITH TYPE 2 DIABETES AND PERIPHERAL ARTERIAL DISEASE: TRIAL DESIGN AND BASELINE CHARACTERISTICS FROM STRIDE A 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Bonaca, Marc P.
Catarig, Andrei-Mircea
Hansen, Yasemin
Houlind, Kim
Ludvik, Chethana R. Bernhard
Nordanstig, Joakim
Rasouli, Neda
Sourij, Harald
Verma, Subodh
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 2231 - 2231

← 1 →